Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00276445|
Recruitment Status : Terminated
First Posted : January 13, 2006
Last Update Posted : November 7, 2006
|Condition or disease||Intervention/treatment||Phase|
|Allergic Conjunctivitis||Drug: beta-1,3-glucan||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan - A Double-Blind Randomized Study|
|Study Start Date :||January 2004|
|Study Completion Date :||June 2004|
- Symptoms were assessed clinically by score on a allergic symptom rating scale.
- Total IgE and allergen specific IgE were measured.
- The binding capacity of beta-1,3-glucan to peripheral CD14+ cells were assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00276445
|Meiji University of Oriental Medicine|
|Kyoto, Japan, 629-0392|
|Principal Investigator:||Jun Yamada, M.D. Ph.D.||Meiji University of Oriental Medicine|
|Study Director:||Junji Hamuro, Ph.D.||Kyoto Prefectural University of Medicine|
|Study Chair:||Shigeru Kinoshita, M.D. Ph.D.||Kyoto Prefectural University of Medicine|